Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 18;140(7):782-785.
doi: 10.1182/blood.2022016317.

Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders

Jennifer La  1 , Julie Tsu-Yu Wu  1   2   3 , Westyn Branch-Elliman  1   4   5 , Linden Huhmann  1 , Summer S Han  1   6 , Mary Brophy  1   7 , Nhan V Do  1   7   8 , Albert Y Lin  1   2   3 , Nathanael R Fillmore  1   5   9 , Nikhil C Munshi  5   9   10
Affiliations

Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders

Jennifer La et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative incidence and HRs for breakthrough infection in patients with MM or MGUS. (A) Cumulative incidence curves of any breakthrough SARS-COV-2 infection by disease state shown using time zero as 14 days after the day of second dose of vaccination. CIs were calculated by bootstrapping. The number at risk are also shown. (B) HRs for infection separated by disease state and COVID severity. Hazards are calculated separately for risk of any breakthrough infection and risk of severe breakthrough infection relative to matched controls. All hazards were calculated using Fine-Gray competing risk regression with the competing risk of death.
See this image and copyright information in PMC

References

    1. Chari A, Samur MK, Martinez-Lopez J, et al. . Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26): 3033-3040. - PMC - PubMed
    1. Wang L, Berger NA, Xu R. Risks of SARS-CoV-2 breakthrough infection and hospitalization in fully vaccinated patients with multiple myeloma. JAMA Netw Open. 2021;4(11):e2137575. - PMC - PubMed
    1. Terpos E, Trougakos IP, Gavriatopoulou M, et al. . Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021;137(26):3674-3676. - PMC - PubMed
    1. Henriquez S, Zerbit J, Bruel T, et al. . Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in multiple myeloma patients. Blood. 2022;139(6):942-946. - PMC - PubMed
    1. Van Oekelen O, Gleason CR, Agte S, et al. ; PVI/Seronet team . Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39(8):1028-1030. - PMC - PubMed

Publication types

Substances

Supplementary concepts